Compared of immunogenicity and protein composition of experimental and officinal virosomal influenza virus vaccine

A Volyanskiy; M Pogorila; E Romanova; T Davidova; A Martynov; N Igumnova; T Sidorenko; V Yukhimenko; S Peremot; M Smilianska; N Kashpur

Автор(и)

A Volyanskiy Mechnikov Institute of Microbiology and Immunology,
M Pogorila Mechnikov Institute of Microbiology and Immunology,
E Romanova Mechnikov Institute of Microbiology and Immunology,
T Davidova Mechnikov Institute of Microbiology and Immunology,
A Martynov Mechnikov Institute of Microbiology and Immunology,
N Igumnova Mechnikov Institute of Microbiology and Immunology,
T Sidorenko Mechnikov Institute of Microbiology and Immunology,
V Yukhimenko Mechnikov Institute of Microbiology and Immunology,
S Peremot Mechnikov Institute of Microbiology and Immunology,
M Smilianska Mechnikov Institute of Microbiology and Immunology,
N Kashpur Mechnikov Institute of Microbiology and Immunology,

Ключові слова:

virosomal trivalent influenza vaccine, protein composition, immunogenicity.

Анотація

Introduction Due to the high mutagenicity that distinguishes influenza A virus, there are viruses of this type of new antigenic properties, the prevention of which the immune system has no immunological memory. It is therefore important to find new ways to create and study patterns of immunological impact of influenza vaccines. The success of liposomal vaccines and the growing interest in their improvement can be attributed to a number of key advantages over other systems of delivery of antigens and enhance the immune response. The main advantage of liposomes is their safety and good tolerance, as demonstrated by the use of approved based on liposomes of anticancer and anti-infective drugs. Material and methods As part of the search for new ways to create, study functional characteristics and patterns of immunological impact of influenza vaccine immunogenicity was investigated newly formed liposomal vaccine "Lipos 2" compared to the trivalent vaccine officinal virosomal vaccine Infleksal and analyzed their protein composition using bioanalyzer «Agilent 2100." Immunogenicity of vaccines studied by hemagglutination inhibition test (HIT) with a specific antigen (influenza virus). The composition of proteins containing vaccine was studied using bioanalyzer «Agilent-2100» («Agilent Technologies», USA) using the method of SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Analysis on «Agilent-2100" conducted by using chips to analyze 12 samples simultaneously studied vaccines. The protein composition of the vaccine was determined by elektrophoregram receiving data on molecular weight protein fragments, their concentration and percentage of study medication. Also, determine the average number of proteins in vaccine strain. Results and discussion Considerable experimental vaccine immunogenicity, which caused a persistent increase in the level of specific antibodies to all three viral antigens in most experimental animals compared with the vaccine, which was in control. Based elektroforegram defined the quantitative composition of proteins, their total weight and percentage of trivalent subunit vaccine Inflyuvak and trivalent virosomal vaccine Infleksal, that the number of components of different protein components by molecular weight.

Посилання

Flu information bulletin №211 [E-sourse]. March 2014.

www. who. int/ mediacentre/factsheets/fs21.

Herzog C. Eleven years of Inflexal V - a virosomal adjuvanted influenza vaccine [Text]. / C. Herzog, K. Hartmann, V. Kunzi, O. Kursteiner, R. Mischler, H. Lazar, et al. // Vaccine. 2009 Jul 16. - V.27., №33. – P. 4381–4387.

Mischler R. Inflexal V a trivalent virosome subunit influenza vaccine: production [Text]. / R. Mischler, I.C. Metcalfe. // Vaccine. 2002 Dec 20. - V.20., №5.- Р.17–23.

Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection [Text]. / PA. Bovier // Expert Rev. Vaccines. 2008 Oct. - V.7., №8. – P.1141–1150.

Usonis V. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal) [Text]. / V. Usonis, V. Bakasenas, R. Valentelis, G. Katiliene, D. Vidzeniene, C. Herzog // Vaccine. 2003 Nov 7. - V.21., №31. – P.4588–4592.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [Text]. / C. Butts, N. Murray, A. Maksymiuk, G. Goss, E. Marshall, D. Soulieres et al. // J Clin Oncol. 2005 Sep 20. - V.23., №27. – P.6674–6681.

North S. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers [Text]. / S. North, C. Butts. // Expert Rev Vaccines. 2005 Jun- V.4., №3. – P.249–57.

Regules JA. The RTS,S vaccine candidate for malaria [Text]. / JA. Regules, JF. Cummings, CF. Ockenhouse. // Expert Rev Vaccines. 2011 May. - V.10., №5. – P.589–599.

Agnandji ST. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization [Text]. / ST. Agnandji, KP. Asante, J. Lyimo, J. Vekemans et al. // J Infect Dis. 2010 Oct 1. - V.202., №7. – P.1076–1087.

Torchilin VP. Recent advances with liposomes as pharmaceutical carriers [Text]. / VP. Torchilin // Nat Rev Drug Discov.2005 Feb. - V.4., №2. – P.145–160.

Tollemar J. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children [Text]. / J. Tollemar, L. Klingspor, O. Ringden. // Clin Microbiol Infect. 2001. - V.7., №2. – P.68–79.

Stewart S, Randomized comparative trial of pegylated iposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma [Text]. / S. Stewart, H. Jablonowski, FD. Goebel, K. Arasteh, et al. // International Pegylated Liposomal Doxorubicin Study Group. J of Clinical Oncology. 1998. - V.16., №2. – P.683–691.

Fries LF. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy [Text]. / LF. Fries, Gordon DM, Richards RL, Egan JE, et al. // Proc Natl Acad Sci U S A. 1992 Jan 1. - V.89., №1. – P.358–362.

Agnandji ST, First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children [Text]. / ST Agnandji, B. Lell, SS. Soulanoudjingar, JF. Fernandes, BP. Abossolo, C. Conzelmann, et al. // N Engl J Med. 2011 Nov 17. - V.365., №20. – P.1863–1875.

Europian Convention for the protection of vertebrate animals used for experimental and other scientific purposes [Text]. Strasburg: Council Treaty Series; 1986. - 123 р.

Lapach SN. Statistical methods in medical-biological studies using Excel. / SN. Lapach. - Kyiv: Моrion., 2004. – p.

Buktimirov TA. Methods for determination of quality of immunobiological preparations for the prevention and diagnosis of influenza: Guidance. / TA. Buktimirov, NI. Lonskaya, NA. Agafonova, et al. - M.: Federal Centre for Sanitary Inspection Ministry of Health of Russia, 2003 – 32 p.

Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 [Text] / Laemmli U. K. / Nature.-1970. –V.227. – P.680-685.

Osterman L. А. Methods of study of proteins and nucleic acids [Теxt] / L. А. Osterman. –М.: МCCМI, 2002. - 248 p.

Method of spectrophotometric determination of concentration of Liposomally bagged pharmaceutical preparations. Patent RF №2337358, Date of publication 27.10 2008, Application 03.04.2007. Filinova EJ., Kiselev SM, Solov'ev AI.

Chaloupka I. Coparative analisis of six European influenza vaccines [Text] / I. Chaloupka., A. Schuler, M. Marshall. // Eur.J.Clin.Microbiol.Infect.Dis. – 1996. – V.15. – P.121-127.